Trials / Conditions / Stage II Pancreatic Cancer

Stage II Pancreatic Cancer

22 registered clinical trials studyying Stage II Pancreatic Cancer.

Status	Trial	Sponsor	Phase
Active Not Recruiting	Trametinib and Hydroxychloroquine in Treating Patients With Pancreatic Cancer NCT03825289	University of Utah	Phase 1
Completed	VX15/2503 and Immunotherapy in Resectable Pancreatic and Colorectal Cancer NCT03373188	Emory University	Phase 1
Completed	Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer NCT03154190	Stanford University	N/A
Completed	Chemotherapy, Stereotactic Body Radiation Therapy & Nelfinavir Mesylate in Locally Advanced Pancreatic Cancer NCT01959672	University of Nebraska	Phase 2
Completed	Chemotherapy and Radiation Therapy Before Surgery Followed by Gemcitabine in Treating Patients with Pancreatic NCT01821612	Alliance for Clinical Trials in Oncology	EARLY_Phase 1
Completed	Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Chemotherapy and Radiation Therapy for Pan NCT01534637	Wake Forest University Health Sciences	Phase 2
Completed	Eribulin Mesylate as Second-Line Therapy for Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer P NCT00383760	National Cancer Institute (NCI)	Phase 2
Completed	Capecitabine, Bevacizumab, and Radiation Therapy Followed By Gemcitabine and Bevacizumab in Treating Patients NCT00114179	National Cancer Institute (NCI)	Phase 2
Completed	Radiotherapy Combined With Oxaliplatin and Fluorouracil Followed By Gemcitabine in Treating Patients With Loca NCT00096070	National Cancer Institute (NCI)	Phase 2
Completed	Sorafenib and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer NCT00095966	National Cancer Institute (NCI)	Phase 2
Completed	Bevacizumab and Gemcitabine Combined With Either Cetuximab or Erlotinib in Treating Patients With Advanced Pan NCT00091026	National Cancer Institute (NCI)	Phase 2
Completed	Gemcitabine With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Ca NCT00088894	National Cancer Institute (NCI)	Phase 3
Terminated	EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer NCT00087191	National Cancer Institute (NCI)	N/A
Completed	CCI-779 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer NCT00075647	National Cancer Institute (NCI)	Phase 2
Completed	Erlotinib, Gemcitabine, and Radiation Therapy in Treating Patients With Locally Advanced Unresectable Pancreat NCT00063947	National Cancer Institute (NCI)	Phase 1
Completed	Flavopiridol Plus Radiation Therapy Followed By Gemcitabine Hydrochloride in Treating Patients With Locally Ad NCT00047307	National Cancer Institute (NCI)	Phase 1
Completed	UCN-01 and Gemcitabine in Treating Patients With Unresectable or Metastatic Pancreatic Cancer NCT00039403	National Cancer Institute (NCI)	Phase 1
Completed	Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction NCT00030498	National Cancer Institute (NCI)	Phase 1
Completed	Combination Chemotherapy Plus Radiation Therapy With or Without Tipifarnib in Treating Patients With Locally A NCT00026104	National Cancer Institute (NCI)	Phase 2
Completed	Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer NCT00028496	National Cancer Institute (NCI)	Phase 1
Completed	Vaccine Therapy in Treating Patients With Colon, Pancreatic, or Lung Cancer NCT00019006	National Cancer Institute (NCI)	Phase 1
Withdrawn	Gemcitabine Hydrochloride With or Without Bevacizumab in Treating Patients Who Are Undergoing Surgery for Panc NCT00253526	National Cancer Institute (NCI)	Phase 2